Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Transplant Surgery
  •  Pediatric Surgery
  •  Plastic Surgery
  •  Thoracic Surgery
  •  General Surgery
  •  Surgical Oncology
  •  Minimally Invasive Surgery
  •  Bariatric Surgery

Abstract

Citation: Clin Surg. 2018;3(1):2056.Research Article | Open Access

Rivaroxaban Treatment in Acute Proximal DVT Patients with Malignancy

Chiu-Yang Lee

Department of Surgery, Division of Cardiovascular Surgery, Taipei Veterans General Hospital, Taiwan
Department of Senior Citizen Service Management, Chia Nan University of Pharmacy and Science, Taiwan

*Correspondance to: Chiu-Yang Lee 

 PDF  Full Text DOI: 10.25107/2474-1647.2056

Abstract

Background: The primary objective of this study was to evaluate efficacy and safety of rivaroxaban treatment in patients with active malignancy and acute proximal deep vein thrombosis (DVT).Methods: This study comprised 34 patients with active cancer and acute proximal DVT, who received rivaroxaban treatment for at least 5 months. The study endpoints included the rate of thrombus regression, treatment efficacy and safety, which were assessed with frequent duplex ultrasounds, plethysmography, and commutated tomography. The mean duration of the follow-up was 25.2 months.Results: Of 34 patients with cancer, 31 suffered from active malignancy. 15 patients had breast carcinoma, and 5 had lung cancer in this study. At 3, 6, 12, and 24 months, cumulative patency was observed in 11.8%, 38.2 %, 44.1%, and 55.90% of all patients. Femoral valvular incompetence was found in 21 (61.8%) patients. 19 patients developed post thrombositc syndrome (PTS) at 12 months, and the mean PTS score was 5.9 ± 3.3. Of 34 patients, 9 patients had bleeding events. 9 (26.5%) patients developed recurrent deep vein thrombosis, and 3(7.5%) had pulmonary embolism during follow-up.Conclusion: This study indicated extended-duration rivaroxaban therapy should be considered for acute unprovoked proximal DVT. Large-scale prospective studies should be conducted in cancer associated DVT patients in the future.

Keywords

Deep vein thrombosis; Post-thrombotic syndrome; Valvular incompetence

Cite the article

Lee C-Y. Rivaroxaban Treatment in Acute Proximal DVT Patients with Malignancy. Clin Surg. 2018; 3: 2056.

Search Our Journal

Journal Indexed In

Articles in PubMed

RAF Kinase Inhibitory Protein Expression and Phosphorylation Profiles in Oral Cancers
 PubMed  PMC  PDF  Full Text
Monitoring an Ongoing Enhanced Recovery after Surgery (ERAS) Program: Adherence Improves Clinical Outcomes in a Comparison of Three Thousand Colorectal Cases
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Ultrasound in Medical Education: Increasing Awareness for Ultrasound Applications in the Novice Learner
 Abstract  PDF  Full Text
Automated Sagittal Craniosynostosis Classification from CT Images Using Transfer Learning
 Abstract  PDF  Full Text
View More...